SCHEMBL8444089

SCHEMBL8444089

C=Cc1cc(OC)c2c(OCCOC)cc3cccnc3c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.45
MAPT P10636 4/20 0.45
GAA P10253 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 3/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
PDE10A Q9Y233 1/20 0.37
POLB P06746 2/20 0.36
SLC40A1 Q9NP59 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
DYRK1A Q13627 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
NFKBIA P25963 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473268 0.89 NPC1 (0.44) LMNAMAPTGAASMN1; SMN2MAPK1
SCHEMBL13372654 0.86 HSP90AA1 (0.40) LMNAMAPTGAASMN1; SMN2MAPK1
SCHEMBL2478976 0.86 HSP90AA1 (0.40) LMNAMAPTGAASMN1; SMN2MAPK1
SCHEMBL2475172 0.86 HSP90AA1 (0.40) LMNAMAPTGAASMN1; SMN2MAPK1
SCHEMBL8444087 0.81 LMNA (0.38) LMNAMAPTGAASMN1; SMN2MAPK1
SCHEMBL2472272 0.81 PDE10A (0.43) LMNAMAPTGAASMN1; SMN2MAPK1
SCHEMBL2472998 0.78 ALDH1A1 (0.45) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2805108 0.70 RAB9A (0.43) LMNAMAPTGAASMN1; SMN2MAPK1
SCHEMBL2479017 0.69 NPC1 (0.40) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2471610 0.68 NFKBIA (0.40) LMNAMAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010066832-A1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER NOSCIRA, S.A. (ES) 2010-06-17 WO disclosed
EP-2196466-A1 Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions NOSCIRA, S.A. (ES) 2010-06-16 EP disclosed